Clinical trial
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic…
NCT00109538 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00109538 |
|---|---|
| Title | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) |
| Official title | A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Myelodysplasia |
| Intervention type | Drug, Other |
| Interventions | Lonafarnib, Placebo |
| Enrollment | 47 |
| Start date | May 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Apr 29, 2005 |
| Last update posted | May 1, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: